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Abstract
Background: Inhaled corticosteroids (ICS) are effective maintenance treatments for childhood asthma; however,
many children remain uncontrolled. Vilanterol (VI) is an inhaled long-acting beta-2 agonist which, in combination
with the ICS fluticasone furoate, is being explored as a once-daily treatment for asthma in children. We evaluated
the dose–response, efficacy, and safety of once-daily VI (6.25 μg, 12.5 μg and 25 μg) administered in the evening
over 4 weeks, on background fluticasone propionate (FP) in children with asthma inadequately controlled on ICS.
Methods: This was a Phase IIb, multicentre, randomised, double-blind, parallel-group, placebo-controlled study in
children ages 5–11 years with persistent asthma on ICS and as-needed short-acting beta-agonist. The study comprised
a 4-week run-in, 4-week treatment period, and 1-week follow-up. From study start, children replaced their current ICS
with open-label FP 100 μg twice daily. Children were randomised to receive placebo, VI 6.25 μg, VI 12.5 μg or VI 25 μg
once daily. Primary endpoint was treatment difference between VI 25 and placebo groups in mean change from
baseline in evening peak expiratory flow averaged over the 4-week treatment. Secondary endpoints included
change from baseline in trough forced expiratory volume in one second (FEV1) at Week 4 and change from
baseline in percentage of rescue-free and symptom-free 24-h periods. Safety assessments included incidence of
adverse events (AEs) and asthma exacerbations.
Results: In total, 456 children comprised the intention-to-treat population. The adjusted treatment difference
between VI 25 and placebo groups for the primary endpoint was not statistically significant (p = 0.227) so no
statistical inference was made for other VI dose comparisons or other endpoints. No difference in change from
baseline in trough FEV1 was observed for any VI treatments versus placebo; however, VI 25 resulted in an additional 0.6
rescue-free days and 0.7 symptom-free days per week versus placebo. The incidence of AEs was slightly higher in the VI
groups (28–33 %) versus placebo (22 %). Nine children experienced asthma exacerbations during the treatment period.
Conclusion: VI plus FP did not result in significant improvements in lung function versus placebo plus FP, but was
well tolerated at all doses assessed.
Trial registration: NCT01573767 (ClinicalTrials.gov).
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Background
Asthma is common in children and is a leading cause of
childhood hospitalisation [1]. National and international
guidelines advocate the use of inhaled long-acting beta-2
agonists (LABA) in combination with inhaled cortico-
steroids (ICS) as maintenance therapy for children ages
5–11 years who remain symptomatic despite medium
doses of ICS [2, 3]. A network meta-analysis including
over 12,000 patients across 35 studies found that com-
bined ICS/LABA treatments were more effective than
low-dose ICS in preventing asthma exacerbations among
paediatric patients [4]. In addition, studies indicate that
the addition of LABA to a low dose of ICS can provide
benefits such as improved asthma control in some chil-
dren compared with increasing the ICS dose [5] and a re-
duced impact on growth by 1.2 cm/year compared with
double the dose of ICS [6].
Despite the availability of effective therapies, many chil-
dren with asthma remain uncontrolled, with low adherence
proposed as a potential contributing factor [7, 8]. In
addition, studies in adult and adolescent patients using
dry powder inhalers for treatment of asthma and chronic
obstructive pulmonary disease have shown that adherence
with a once-daily regimen is greater than with a twice-
daily regimen [9, 10]. However, currently available ICS/
LABA combination therapies require a twice-daily regi-
men [11, 12].
Vilanterol (VI) is a potent, inhaled LABA which, in
combination with the ICS fluticasone furoate (FF), has
been approved for the treatment of asthma in adults and
adolescents in the EU, and in adults in the US [13–15].
In preclinical in vitro studies, VI demonstrated a select-
ivity profile for beta-2 adrenoceptors (over beta-1 and
beta-3 adrenoceptors) that was similar to salmeterol and
greater than formoterol and indacaterol [16]. Persistence
and reassertion studies also showed a persistence of
action comparable with indacaterol and greater than
formoterol [16]. VI is currently being explored as the
LABA component of FF/VI for once-daily treatment
for asthma in children [17]. The objective of this study
was to evaluate the dose–response, efficacy, and safety of
three doses of VI (6.25 μg, 12.5 μg and 25 μg) adminis-
tered once daily in the evening over a 4-week treatment
period whilst on background fluticasone propionate (FP)
therapy to children with asthma who were inadequately
controlled on ICS.
Methods
Study design
This was a Phase IIb, multicentre, randomised, double-
blind, parallel-group, placebo-controlled (with rescue
medication) study in children ages 5–11 years with persist-
ent asthma who were still symptomatic on low-dose ICS
(ClinicalTrials.gov identifier NCT01573767). The study
design consisted of a 4-week run-in period, a 4-week
treatment period and a 1-week follow-up (contact)
period. At the start of the run-in period, children re-
placed their current asthma medication with open-label
FP 100 μg twice daily via DISKUS®/ACCUHALER®
(GlaxoSmithKline), which they continued to take for the
duration of the study. A total of 73 centres in 14 countries
(Argentina, Chile, Georgia, Germany, Japan, Mexico, Peru,
Philippines, Poland, Puerto Rico, Slovakia, South Africa,
United States of America and Ukraine) randomised
subjects.
Participants
Children eligible for inclusion were males and pre-
menarchial females with inadequately controlled asthma,
ages 5–11 years, with at least a 6-month history of asthma
and who had been receiving a stable dose of a ICS (total
daily dose of FP 200–250 μg or equivalent) and rescue
short-acting inhaled beta-agonist (SABA) for at least
4 weeks prior to screening. Eligible children had a pre-
bronchodilator peak expiratory flow (PEF) of 50−90 % of
their best post-bronchodilator value. Excluded children
had: a history of life-threatening asthma; a change in
asthma medication within 4 weeks of screening; an
asthma exacerbation (defined as either requiring the
use of systemic corticosteroids for ≥3 days, a depot cor-
ticosteroid injection within 3 months prior to screening,
or hospitalisation for asthma within 6 months prior to
screening); or a concurrent respiratory disease or any
other clinically significant medical condition.
At the end of the run-in period, children eligible for ran-
domisation had a pre-bronchodilator PEF of 50−90 % of their
best post-bronchodilator value, had demonstrated symptoms
of asthma and/or daily use of albuterol/salbutamol on
≥3 of the last 7 consecutive days of the run-in period,
complied with the run-in medication on ≥4 of the last 7
consecutive days of the run-in period and had com-
pleted all questions on the Daily Diary on ≥4 out of the
7 days during the screening period. Children could not
have experienced an asthma exacerbation between
screening and randomisation.
The study was conducted in accordance with the eth-
ical principles outlined in the Declaration of Helsinki
and was approved by the relevant ethics committee or
institutional review board at each investigational centre.
Written informed consent was obtained from two parents/
legal guardians. If applicable, the child had to be able and
willing to give assent to take part in the study according to
the local requirements. The investigator was accountable
for determining a child’s capacity to assent.
Treatment and assessments
Children were randomly assigned (1:1:1:1) to receive ei-
ther placebo, VI 6.25 μg, VI 12.5 μg, or VI 25 μg once
Oliver et al. Respiratory Research  (2016) 17:37 Page 2 of 11
daily as their double-blind evening treatment (between
3 pm and 9 pm) in addition to continuing open-label FP
100 μg twice daily. Randomisation was performed via an
interactive voice response system whereby children were
assigned a randomisation number from a randomisation
schedule created by GSK. Children were issued with a
daily eDiary and a peak flow meter, and recorded morn-
ing and evening PEF, daytime and night time asthma
symptom scores, day and night inhalations of SABA and
the use of open-label ICS medication during the run-in
period. Pre-dose forced expiratory volume in one second
(FEV1) was measured electronically by spirometer at
evening study visits at screening, randomisation, Week 2
and Week 4. These measurements were taken within ±1 h
of the time FEV1 was measured at baseline and approxi-
mately 24 h after the child’s last evening dose. Children
who were unable to perform acceptable quality FEV1 at
randomisation did not have to perform the spirometry as-
sessments at subsequent study visits, however, data from
these children were still collected for all other endpoints.
The primary endpoint was the mean change from base-
line in daily pre-dose trough evening PEF, recorded using
an eDiary, averaged over the 4-week treatment period.
Secondary endpoints were: 1) change from baseline in
evening study visit trough FEV1 at the end of the 4-week
treatment period (using last observation carried forward
[LOCF] for imputation of missing post-baseline FEV1
values); 2) change from baseline in percentage of rescue-
free and symptom-free 24-h periods averaged over the
4-week treatment period; 3) change from baseline in
morning PEF averaged over the 4-week treatment period;
and 4) mean change from baseline in morning and even-
ing PEF over the last 7 days of the treatment period. Other
endpoints were change from baseline in childhood asthma
control test (cACT) score at the end of the 4-week treat-
ment period and the percentage of subjects controlled,
defined as a cACT score ≥20. A post-hoc analysis was
carried out to determine the change from baseline in
cACT score according to whether children had a base-
line cACT score of <20 or ≥20.
Pharmacokinetic (PK) blood samples were collected
pre-dose and 10−15 min post-dose during the Week 4
visit. Plasma samples were analysed for VI using tech-
niques based on solid phase extraction followed by high-
performance liquid chromatography and tandem mass
spectrometry analysis (the lower limit of quantification
[LLQ] was 10 pg/mL, using a 200 μL aliquot).
Safety was assessed by incidence of adverse events
(AEs) and exacerbations throughout the 4-week treat-
ment period; vital signs (pulse rate, systolic and diastolic
blood pressure [BP]) at randomisation and at Week 2,
Week 4 or early withdrawal; pre-dose and post-dose elec-
trocardiogram (ECG) at randomisation and at Week 4 or
early withdrawal; and laboratory assessments (haematology,
clinical chemistry and liver function tests) at screening,
Week 4 or early withdrawal.
Statistical analysis
With 460 children (115 per treatment group) the study
had 90 % power assuming a difference of 12 L/min be-
tween VI and placebo in evening PEF, a standard devi-
ation of 28 L/min and significance declared at the
two-sided 5 % level. In order to account for multipli-
city across treatment comparisons for the primary effi-
cacy endpoint, a step-down closed testing procedure
was applied whereby inference for VI 12.5 μg versus
placebo was dependent upon statistical significance
having first been achieved for VI 25 μg versus placebo.
Similarly, inference for VI 6.25 μg versus placebo was
dependent upon statistical significance having first been
achieved for VI 12.5 μg versus placebo.
The intention-to-treat (ITT) population comprised all
children randomised to treatment who received ≥1 study
medication; the per-protocol (PP) population comprised
all children in the ITT population who did not have any
full protocol deviations; and the PK population consisted
of children in the ITT population for whom a PK sample
was obtained and analysed for VI.
The analysis of the primary efficacy endpoint was
performed using an analysis of covariance (ANCOVA)
model allowing for the effects due to baseline evening
PEF, region, sex, age and treatment group on the ITT
and PP populations. Missing data were not imputed in
this analysis. Five sensitivity analyses were performed
to examine the impact of missing data on the primary
endpoint: one mixed modelling repeated measures
(MMRM) model analysis, and four multiple imputation
sensitivity analyses. The MMRM analysis allowed for
effects due to baseline evening PEF, region, sex, age,
week and treatment group, including week-by-treatment
and week-by-baseline interaction terms. The four imput-
ation sensitivity analyses analysed the mean change from
baseline in evening PEF using a Missing at Random ap-
proach, a Copy Increment from Reference approach, a
Jump to Reference approach and a Copy Reference ap-
proach. An average treatment effect across Weeks 1−4
was obtained for all sensitivity analyses of the primary
endpoint. Three further supporting analyses were also per-
formed on the primary endpoint; these were dose response
models, Bayesian analyses with non-informative priors and
a MMRM model presenting estimates from each week.
Statistical analyses for secondary endpoints were per-
formed using ANCOVA models with effects due to base-
line, region, sex, age and treatment group. For trough
FEV1 and morning/evening PEF at the endpoint, missing
data was imputed using LOCF. Programming was per-
formed using SAS Version 9.1.3 or later.
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Percent predicted FEV1 values at screening and base-
line were not pre-specified and are reported as posthoc
analyses.
Results
Demographics
A total of 1208 children were screened; 463 children
were randomised with 456 (98 %) children included in
the ITT population (Fig. 1). Overall, 81 (18 %) children
withdrew prematurely from this 4-week study, the major-
ity (62 children, 14 %) withdrawing due to lack of efficacy.
The study period, from the first screening to the last visit,
was from April 2012 to April 2014. Demographics were
comparable between the four treatment groups and are
summarised in Table 1. Lung function measures at screen-
ing and baseline are shown in Table 2. PEF and FEV1
values were similar across treatment groups and stable
during the run-in period with open-label FP.
Primary endpoint
The adjusted treatment differences in the mean change
from baseline in daily pre-dose trough evening PEF ver-
sus placebo were 5.5 L/min, 6.4 L/min and 4.4 L/min,
for the VI 6.25, VI 12.5 and VI 25 groups, respectively
(Fig. 2 and Table 3). The adjusted treatment difference
between the VI 25 and placebo groups was not statistically
significant (p = 0.227). Therefore, in accordance with the
step-down closed testing procedure, no statistical infer-
ence was made for the comparisons of VI 12.5 μg or VI
6.25 μg with placebo. The analysis of the primary endpoint
using the PP population plus all sensitivity and supporting
analyses using the ITT population supported the findings
of the primary analysis. There was no apparent VI dose-
ordering in the evening PEF treatment difference values
from placebo.
Secondary endpoints
Since the primary endpoint did not reach statistical sig-
nificance, no inference was made for the secondary end-
points. A total of 384 (84 %) children completed a
technically acceptable pre-bronchodilator FEV1 assessment
at baseline. Of these, a total of 323 (71 %) children and 291
(64 %) children also completed an acceptable FEV1 assess-
ment at Week 2 and Week 4, respectively. The analysis of
change from baseline in trough FEV1 at Week 4 (LOCF)
included 340 (75 %) children in the ITT population who
provided technically acceptable FEV1 data both at baseline
and at post-baseline. There was little difference in the
change from baseline in trough FEV1 at Week 4 for each
of the VI treatments compared with placebo (Table 3).
Over the treatment period, the greatest treatment dif-
ference in change from baseline in the percentage of
rescue-free 24-h periods was observed in the VI 25 treat-
ment group when compared with placebo (Table 3). This
equated to an additional 0.6 rescue-free 24-h periods per
week for children. For symptom-free days, the treatment
differences observed between placebo and the VI 12.5
and VI 25 treatment groups, respectively, equate to an
additional 0.6 and 0.7 symptom-free days per week. No
Assessed for eligibility
(N=1208)
Entered run-in (N=760)
Randomised (N=463)
Intention-to-treat
population
(N=456)
Excluded (N=448)
Not meeting inclusion criteria (n=442)
Physician decision (n=4)
•
•
• Withdrawal by subject (n=2)
Run-in failures (N=295)
• Not meeting continuation criteria
(n=268)
• Withdrawal by subject (n=13)
• Physician decision (n=10)
• Lost to follow-up (n=3)
• Study terminated by sponsor (n=1)
Completed the run-in period and 
received study treatment without 
being randomised (n=2)
Randomised but did not 
receive study medication
(n=7)
•
•
•
•
•
•
Completed (n=93)
Withdrew due to:
Placebo (n=115)
Lack of efficacy (n=18)
Protocol deviation (n=3)
Investigator discretion (n=1)
Lost to follow-up (n=0)
Adverse event (n=0)
Withdrew consent (n=0)
VI 6.25 (n=114)
Completed (n=93)
Withdrew due to:
• Lack of efficacy (n=15)
• Protocol deviation (n=1)
• Investigator discretion (n=2)
• Lost to follow-up (n=1)
• Adverse event (n=1) 
• Withdrew consent (n=1)
VI 12.5 (n=113)
Completed (n=99)
Withdrew due to:
• Lack of efficacy (n=12)
• Protocol deviation (n=1)
• Investigator discretion (n=0)
• Lost to follow-up (n=1)
• Adverse event (n=0)
• Withdrew consent (n=0)
VI 25 (n=114)
Completed (n=90)
Withdrew due to:
• Lack of efficacy (n=17)
• Protocol deviation (n=3)
• Investigator discretion (n=2)
• Lost to follow-up (n=1)
• Adverse event (n=1)
• Withdrew consent (n=0)
Fig. 1 Participant flow diagram. Abbreviations: VI, vilanterol
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difference in rescue-free or symptom-free days was
found for the VI 6.25 group.
Across all secondary PEF endpoints, small but non-
significant increases were seen with VI treatments
compared with placebo. However, as with the primary
endpoint, no dose–response was observed (Table 3).
Children whose asthma was controlled at baseline
(cACT score ≥20) experienced only small improvements
in cACT score following treatment with VI compared
with placebo, whereas in children with a cACT score <20
at baseline, larger increases were observed (Table 3).
Pharmacokinetics
In total, 341 children (PK population) provided 780 PK
samples. There was a very high proportion of pre-dose
samples with non-quantifiable levels of VI, especially in
the two lower dose groups (91, 94 and 74 % for the VI
6.25, VI 12.5 and VI 25 populations, respectively). At
10−15 min post-dose, the proportion of samples below
the LLQ was 48, 30 and 20 % for the VI 6.25, VI 12.5
and VI 25 groups, respectively. The concentration-time
data for the current study were combined with data from
previous studies conducted in children with asthma re-
ceiving either VI 25 μg alone [18] or in combination
with FF [17]. The mean plasma concentrations of VI 10
−15 min post-dose were dose ordered and as expected for
the doses administered (17.27 pg/mL, 40.04 pg/mL and
90.47 pg/mL, after treatment with VI 6.25 μg, VI 12.5 μg
and VI 25 μg, respectively).
Safety
The incidence of AEs during treatment was higher in
the VI groups (28–33 %) than in the placebo group (22 %),
but there was no apparent dose-ordering (Table 4). The
incidence of AEs considered to be drug-related by the in-
vestigator was 3 and 2 % in the VI 6.25 and VI 12.5
groups, respectively, with none reported in the placebo or
VI 25 groups. The most frequently reported AE during
the treatment period was nasopharyngitis. One child in
each of the VI 6.25 and VI 25 groups experienced an AE
leading to study withdrawal. The child in the VI 25
treatment group experienced an on-treatment non-fatal
Table 1 Summary of demographic characteristics and baseline characteristics (ITT population)
Demographic Placebo VI 6.25 μg VI 12.5 μg VI 25 μg Total
N = 115 N = 114 N = 113 N = 114 N = 456
Sex, n (%)
Female 50 (43) 43 (38) 42 (37) 45 (39) 180 (39)
Male 65 (57) 71 (62) 71 (63) 69 (61) 276 (61)
Age, years
Mean (SD) 8.0 (1.81) 8.0 (1.95) 7.9 (1.74) 7.9 (1.72) 7.9 (1.80)
Age group, n (%)
5–7 years 51 (44) 48 (42) 42 (37) 46 (40) 187 (41)
8–11 years 64 (56) 66 (58) 71 (63) 68 (60) 269 (59)
Race, n (%)
White 68 (59) 63 (55) 55 (49) 62 (54) 248 (54)
White and American Indian or Alaska Native 20 (17) 19 (17) 26 (23) 24 (21) 89 (20)
American Indian or Alaska Native 16 (14) 21 (18) 17 (15) 18 (16) 72 (16)
Asian 6 (5) 6 (5) 7 (6) 6 (5) 25 (5)
African American/African heritage 5 (4) 5 (4) 5 (4) 3 (3) 18 (4)
White and African American/African heritage 0 0 2 (2) 0 2 (<1)
African American/African heritage and American Indian or Alaska Native 0 0 1 (<1) 0 1 (<1)
African American/African heritage and Asian 0 0 0 1 (<1) 1 (<1)
Ethnicity, n (%)
Hispanic/Latino 81 (70) 82 (72) 82 (73) 82 (72) 327 (72)
Not Hispanic/Latino 34 (30) 32 (28) 31 (27) 32 (28) 129 (28)
Baseline patient-reported outcomes
Rescue-free 24-h periods (SD), % 18.8 (34.20) 20.3 (35.65) 19.1 (33.73) 17.9 (33.60) -
Symptom-free 24-h periods (SD), % 10.5 (22.50) 7.9 (19.98) 10.2 (22.35) 6.7 (19.30) -
cACT score ≥20, n (%) 58 (50) 49 (43) 48 (42) 46 (40) -
cACT childhood asthma control test, ITT intention-to-treat, SD standard deviation, VI vilanterol
Oliver et al. Respiratory Research  (2016) 17:37 Page 5 of 11
serious AE (SAE) of appendicitis and the child in the VI
6.25 treatment group experienced a viral respiratory
tract infection. Neither AE was judged to be related to
study treatment.
Nine (2 %) children experienced asthma exacerbations
during the treatment period (one child in the placebo
group, three in the VI 6.25 group, one in the VI 12.5
group and four in the VI 25 group). None of these chil-
dren were hospitalised but eight were withdrawn from
the study as a result.
The mean changes from baseline in vital signs at Week
4 were small and similar between the placebo and VI
treatment groups (least squares mean change in systolic
BP: 0.1–1.1 mm Hg; diastolic BP: -0.1–0.4 mm Hg; pulse
rate: -0.7–0.4 beats/min). Similarly, vital sign measure-
ments at Week 2 and the maximum post-baseline changes
showed only minor fluctuations from baseline. Abnormal
ECG findings during the study were considered to be of
potential clinical importance for 12 (3 %) children: two
(2 %) children in the placebo group, six (5 %) children in
the VI 6.25 μg group and two (2 %) children in each of the
VI 12.5 and VI 25 groups. No AEs relating to ECG find-
ings were reported during the study, and no children were
withdrawn due to meeting the protocol-defined ECG
stopping criteria.
Table 2 Lung function measures at screening and baseline
(ITT population)
Lung function
measures
Placebo VI 6.25 μg VI 12.5 μg VI 25 μg Total
N = 115 N = 114 N = 113 N = 114 N = 456
Screening
Pre-bronchodilator PEF (L/min)
n 115 114 113 114 456
Mean 185.05 178.35 179.22 177.09 179.94
SD 59.30 55.67 60.57 55.68 57.74
Post-bronchodilator PEF (L/min)
n 115 114 113 114 456
Mean 238.79 232.29 234.54 228.37 233.51
SD 67.41 69.80 69.79 72.29 69.71
Percentage of pre- to post-bronchodilator PEF (%)
n 115 114 113 114 456
Mean 76.95 76.86 75.87 78.02 76.93
SD 9.18 9.57 10.90 8.17 9.50
Pre-bronchodilator FEV1 (L)
n 91 91 97 102 381
Mean 1.405 1.370 1.374 1.361 1.377
SD 0.408 0.423 0.445 0.429 0.426
Post-bronchodilator FEV1 (L)
n 99 98 96 103 396
Mean 1.700 1.702 1.699 1.680 1.695
SD 0.457 0.532 0.465 0.496 0.487
Pre-bronchodilator FEV1 (% predicted)
a
n 91 91 97 102 381
Mean 86.83 82.92 85.04 84.08 84.70
SD 19.83 17.00 17.34 16.77 17.73
Post-bronchodilator FEV1 (% predicted)
a
n 99 98 96 103 396
Mean 106.81 101.10 104.34 104.58 104.22
SD 20.94 18.47 16.68 19.97 19.15
Baseline
Pre-bronchodilator PEF (L/min)
n 115 114 113 114 456
Mean 186.27 185.08 181.24 179.39 183.00
SD 60.64 59.17 55.19 56.82 57.88
Percentage of pre- to post-bronchodilator PEF (%)
n 115 114 113 114 456
Mean 77.77 79.54 77.58 79.13 78.51
SD 10.49 9.09 10.11 9.77 9.88
Pre-bronchodilator FEV1 (L)
b
n 96 91 97 103 387
Mean 1.367 1.408 1.361 1.365 1.374
SD 0.421 0.454 0.398 0.398 0.416
Table 2 Lung function measures at screening and baseline
(ITT population) (Continued)
Pre-bronchodilator FEV1 (% predicted)
a,b
n 96 91 97 103 387
Mean 84.37 83.99 85.43 85.75 84.91
SD 19.35 16.99 17.66 18.38 18.08
FEV1 forced expiratory volume in one second, ITT intention-to-treat, PEF peak
expiratory flow, SD standard deviation, VI vilanterol
a% predicted FEV1 data are posthoc analyses
bThree children had post-dose FEV1 at baseline and were not included in any
FEV1 secondary endpoint analyses
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Fig. 2 LS mean change from baseline in evening PEF averaged over
Weeks 1 to 4 (ITT population). Abbreviations: ITT, intention-to-treat; LS,
least squares; PEF, peak expiratory flow; SE, standard error, VI, vilanterol
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Table 3 Secondary outcomes (ITT population)
Placebo VI 6.25 μg VI 12.5 μg VI 25 μg
N = 115 N = 114 N = 113 N = 114
Primary endpoint
Mean change from baseline in daily evening PEF Weeks 1–4 (L/min)
n 113 113 112 110
LS mean 215.9 221.4 222.4 220.3
LS mean change (SE) 4.5 (2.53) 10.0 (2.53) 11.0 (2.54) 8.9 (2.56)
Diff. vs placebo 5.5 6.4 4.4
95 % CI −1.6, 12.5 −0.6, 13.5 −2.7, 11.4
p-value 0.127 0.073 0.227
Secondary endpoints
Change from baseline in trough FEV1 (L) at Week 4 (LOCF)
n 85 83 86 86
LS mean 1.616 1.559 1.632 1.586
LS mean change (SE) 0.223 (0.029) 0.166 (0.029) 0.240 (0.029) 0.193 (0.029)
Diff. vs placebo −0.057 0.017 −0.030
95 % CI −0.138, 0.024 −0.063, 0.096 −0.110, 0.051
Change from baseline in percentage of rescue-free 24-h periods, Weeks 1–4
n 113 113 112 110
LS mean change (SE) 14.4 (2.97) 12.2 (2.97) 15.8 (2.98) 23.1 (3.01)
Diff. vs placebo −2.3 1.3 8.7
95 % CI −10.5, 6.0 −6.9, 9.6 0.4, 17.0
Change from baseline in percentage of symptom-free 24-h periods, Weeks 1–4
n 113 113 112 110
LS mean change (SE) 9.9 (2.65) 10.1 (2.65) 18.3 (2.66) 19.7 (2.69)
Diff. vs placebo 0.2 8.3 9.8
95 % CI −7.2, 7.5 1.0, 15.7 2.3, 17.2
Change from baseline in morning PEF (L/min), Weeks 1–4
n 114 113 112 110
LS mean 206.3 211.8 213.8 213.5
LS mean change (SE) 6.4 (2.42) 12.0 (2.43) 13.9 (2.44) 13.7 (2.46)
Diff. vs placebo 5.5 7.5 7.2
95 % CI −1.2, 12.3 0.7, 14.2 0.4, 14.0
Change from Baseline in morning PEF (L/min), endpoint – Week 4 (LOCF)
n 114 113 112 110
LS mean 207.2 213.1 216.9 214.2
LS mean change (SE) 7.4 (3.45) 13.3 (3.47) 17.0 (3.48) 14.4 (3.51)
Diff. vs placebo 5.9 9.7 7.0
95 % CI −3.7, 15.6 0.0, 19.3 −2.7, 16.7
Change from Baseline in evening PEF (L/min), endpoint - Week 4 (LOCF)
n 113 113 112 110
LS mean 217.3 220.8 225.1 222.5
LS mean change (SE) 5.9 (3.44) 9.4 (3.44) 13.7 (3.45) 11.1 (3.48)
Diff. vs placebo 3.5 7.8 5.2
95 % CI −6.1, 13.1 −1.8, 17.4 −4.4, 14.9
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Discussion
In this study, we observed that once-daily inhaled VI
added to a low dose of ICS in children with inadequately
controlled asthma showed no statistically significant
benefit in PEF measurements over placebo, which we
believe also indicates a lack of clinical benefit for this
outcome measure. The small numeric improvements over
placebo in evening PEF following VI treatment were not
statistically significant for the highest dose of 25 μg, and
therefore no inferences were made for the lower doses in-
vestigated in this study. No apparent dose–response was
observed. Therefore, the study was unable to demonstrate
an incremental benefit in selected lung function measures
with the addition of VI to open-label FP in this paediatric
population.
We selected trough (evening) PEF as the primary
endpoint because it was considered a more accessible
measure of lung function than FEV1, as good quality spir-
ometry may be difficult to perform in children [19]. How-
ever, PEF measurements have been reported to be variable
[20, 21] and more so than FEV1 measurements [22]. Thus,
PEF measurements may have introduced a level of under
or over estimation of the treatment benefit. A previous
study of the ICS/LABA combination FP/salmeterol in
children ages 4−11 years, showed an increase in evening
PEF compared with FP alone (mean change [standard
Table 3 Secondary outcomes (ITT population) (Continued)
Other endpoints
Change from baseline in cACT score by baseline category at Week 4a
Baseline cACT Score <20
n 48 57 59 56
LS mean 19.5 19.8 20.2 20.9
LS mean change (SE) 3.5 (0.54) 3.8 (0.49) 4.2 (0.48) 4.9 (0.50)
Diff. vs placebo 0.3 0.7 1.4
95 % CI −1.2, 1.7 −0.7, 2.1 −0.1, 2.9
Baseline cACT Score ≥20
n 50 39 47 36
LS mean 22.9 21.5 21.9 22.5
LS mean change (SE) 0.8 (0.48) −0.5 (0.53) −0.2 (0.48) 0.5 (0.55)
Diff. vs placebo −1.3 −1.0 −0.4
95 % CI −2.8, 0.1 −2.4, 0.4 −1.8, 1.1
cACT childhood asthma control test, CI confidence interval, FEV1 forced expiratory volume in one second, ITT intention-to-treat, LS least squares, PEF peak expira-
tory flow, SE standard error, VI vilanterol
acACT data are post-hoc analyses
Table 4 Most frequent on-treatment AEs by preferred term (ITT population)
AE (preferred term), n (%) Placebo VI 6.25 μg VI 12.5 μg VI 25 μg
N = 115 N = 114 N = 113 N = 114
Children with any AE 25 (22) 33 (29) 37 (33) 32 (28)
Children with most frequent events 15 (13) 27 (24) 26 (23) 18 (16)
Nasopharyngitis 8 (7) 8 (7) 10 (9) 9 (8)
Headache 4 (3) 6 (5) 2 (2) 2 (2)
Rhinitis 3 (3) 2 (2) 3 (3) 1 (<1)
Respiratory tract infection viral 1 (<1) 3 (3) 2 (2) 1 (<1)
Rhinitis allergic 0 2 (2) 3 (3) 2 (2)
Abdominal pain 1 (<1) 0 3 (3) 2 (2)
Bronchitis 2 (2) 3 (3) 1 (<1) 0
Pharyngitis 1 (<1) 3 (3) 0 2 (2)
Influenza 0 4 (4) 0 0
Ear pain 0 0 3 (3) 0
All treatments were administered on a constant background of open-label FP 100 μg twice daily. Table shows events that occurred in ≥3 % in any treatment group
AE adverse event, ITT intention-to-treat, VI vilanterol
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error] from baseline over Weeks 1−12: 21.5 L/min
[2.43] and 15.1 L/min [2.83], respectively) [23]. Further-
more, results of a Cochrane review comparing trials of
6–24 weeks duration in children found that a combin-
ation of LABA and ICS resulted in a significantly
greater improvement in PEF compared with ICS mono-
therapy (morning PEF difference was 7.55 L/min and
evening PEF was 5.5 L/min) [6]. The treatment differ-
ences reported in these analyses are in line with our re-
sults, although statistical significance was not achieved
in this study.
The children in the current study had inadequately
controlled asthma and a mean percentage of pre- to
post-bronchodilator PEF of 76.93 %. Therefore, a benefit
would be expected in these children from the addition
of LABA to their existing ICS therapy. Baseline cACT
scores suggested a high proportion of controlled chil-
dren (40−50 % cACT score ≥20), which could provide a
possible explanation for the lack of efficacy observed in
this study. Another possible reason that no significant
benefit in PEF was observed is that ICS provide good
control of asthma in children, [24] thus reducing the po-
tential for additional improvements in lung function. Of
note, it is possible that children were more adherent to
twice-daily ICS when in the trial compared with an un-
supervised setting, as has been previously reported [25].
The mean pre- and post-bronchodilator FEV1 at
screening was 84.7 and 104.2 %, respectively, suggesting
that children recruited into this study had the potential
for improvement in FEV1 measurements by use of a
bronchodilator. Large increases from baseline in trough
FEV1 at Week 4 (LOCF) were observed for both VI and
placebo treatment groups, hence the small treatment dif-
ferences versus placebo. Considering the small increases
observed in morning and evening PEF, these increases in
FEV1 may have been due to improved ability to perform
spirometric measures over time, by both children and
investigators, in addition to the benefits with ICS and
improved adherence discussed above.
In the secondary efficacy endpoint analyses, an increase
for rescue-free 24-h periods was observed in the VI 25
group compared with placebo. Additionally, notable
increases in symptom-free 24-h periods were observed
for both VI 12.5 and VI 25 groups. The increase in
rescue-free 24-h periods observed in the VI 25 group
and those in symptom-free 24-h periods in the VI 12.5
and VI 25 groups exceed the lower bounds of the pub-
lished minimal important differences in adults [26].
This finding indirectly supports the importance of in-
cluding more than just lung function measurements in
the main analyses of studies in children. Indeed, a large
long-term study in children with asthma aged 5–12
years found that ICS treatment had no effect on lung
function but resulted in improvements in airway
responsiveness and health outcomes over the 4–6-year
treatment period [27].
At the two lower doses of VI, the majority of PK sam-
ples were below quantifiable levels. The mean plasma
concentration of VI 10−15 min post-dose was dose-
ordered and systemic exposure observed for VI 25 μg
was similar to that observed in a Phase IIa study of
FF/VI 100/25 μg in children [18]. As only one post-dose
blood sample was collected, conclusions on maximum
plasma concentration (Cmax) and time to maximum
plasma concentration (tmax) cannot be drawn from this
study. However, studies in adults suggest that VI 25 μg
is rapidly absorbed and eliminated from the systemic
circulation [28, 29] and in children VI 25 μg has been
shown to reach a Cmax shortly after dosing (tmax of
12 min) [18].
The incidence of overall AEs was similar across the VI
treatment groups and slightly higher than in the placebo
group, although there was no dose–response. The most
common on-treatment AEs were those commonly ob-
served in paediatric populations with asthma. The single
SAE reported was not considered to be related to study
treatment and there were no asthma-related hospitali-
sations or fatalities reported. The low number of exac-
erbations in each treatment group prevents meaningful
comparisons between treatments.
Potential limitations of this study were the difficulty in
recruiting children with poorly-controlled asthma on a
background of ICS, and the variability of PEF measure-
ments which may have further masked any treatment
differences. The difficulty in obtaining FEV1 in young
children means that using this as a primary endpoint re-
quires an intensive programme to support coaching
good quality spirometry from all children at all visits.
The high number of study assessments was also a barrier
to recruitment, and we recommend that study assess-
ments are kept to a minimum for studies in children
with asthma. Moreover, additional inclusion criteria
based on cACT score at baseline, reflecting inadequately
controlled asthma, could be used to ensure recruitment
of a more clinically relevant population.
Conclusion
In summary, we found that the three doses of VI inves-
tigated in this study (6.25, 12.5 and 25 μg) did not sig-
nificantly improve the change from baseline in daily
pre-dose trough evening PEF in children ages 5−11 years
and no dose–response was observed in change from base-
line in evening PEF. Notable improvements over placebo
were seen for VI 25 treatment in the percentage of rescue-
free and symptom-free 24-h periods. All treatments were
well tolerated and no new safety concerns were identified
during the study.
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